Among the various agents used in the treatment of severe asthma, in 2021, the use of Tezepelumab (an anti-TSLP antibody) was approved and has shown promising results in treating severe asthma that is both TH-2 and non-TH-2 [11]. Here, TSLP is linked to asthma.